189 related articles for article (PubMed ID: 16470212)
21. Smarter viruses. Onyx pharmaceuticals, Inc.
Wells WA
Chem Biol; 2000 Dec; 7(12):R223-4. PubMed ID: 11137823
[No Abstract] [Full Text] [Related]
22. Oncolytic virotherapy for prostate cancer by E1A, E1B mutant adenovirus.
Satoh M; Wang H; Ishidoya S; Abe H; Moriya T; Hamada H; Arai Y
Urology; 2007 Dec; 70(6):1243-8. PubMed ID: 18158069
[TBL] [Abstract][Full Text] [Related]
23. E1A- and E1B-Double mutant replicating adenovirus elicits enhanced oncolytic and antitumor effects.
Kim J; Kim JH; Choi KJ; Kim PH; Yun CO
Hum Gene Ther; 2007 Sep; 18(9):773-86. PubMed ID: 17725410
[TBL] [Abstract][Full Text] [Related]
24. An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency.
Liu TC; Hallden G; Wang Y; Brooks G; Francis J; Lemoine N; Kirn D
Mol Ther; 2004 Jun; 9(6):786-803. PubMed ID: 15194046
[TBL] [Abstract][Full Text] [Related]
25. A novel E1B-55kD-deleted oncolytic adenovirus carrying mutant KRAS-regulated hdm2 transgene exerts specific antitumor efficacy on colorectal cancer cells.
Liu CC; Liu JH; Wu SC; Yen CC; Chen WS; Tsai YC
Mol Cancer Ther; 2010 Feb; 9(2):450-60. PubMed ID: 20124454
[TBL] [Abstract][Full Text] [Related]
26. Identification of three functions of the adenovirus e4orf6 protein that mediate p53 degradation by the E4orf6-E1B55K complex.
Querido E; Morrison MR; Chu-Pham-Dang H; Thirlwell SW; Boivin D; Branton PE
J Virol; 2001 Jan; 75(2):699-709. PubMed ID: 11134283
[TBL] [Abstract][Full Text] [Related]
27. E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gallbladder cancer.
Fukuda K; Abei M; Ugai H; Seo E; Wakayama M; Murata T; Todoroki T; Tanaka N; Hamada H; Yokoyama KK
Cancer Res; 2003 Aug; 63(15):4434-40. PubMed ID: 12907616
[TBL] [Abstract][Full Text] [Related]
28. Analysis of early region 1 of porcine adenovirus type 3.
Zhou Y; Tikoo SK
Virology; 2001 Dec; 291(1):68-76. PubMed ID: 11878877
[TBL] [Abstract][Full Text] [Related]
29. Distinct regulation of p53 and p73 activity by adenovirus E1A, E1B, and E4orf6 proteins.
Steegenga WT; Shvarts A; Riteco N; Bos JL; Jochemsen AG
Mol Cell Biol; 1999 May; 19(5):3885-94. PubMed ID: 10207112
[TBL] [Abstract][Full Text] [Related]
30. The adenovirus E1B-55K oncoprotein induces SUMO modification of p53.
Muller S; Dobner T
Cell Cycle; 2008 Mar; 7(6):754-8. PubMed ID: 18461721
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of the p53-MDM2 interaction by adenovirus delivery of ribosomal protein L23 stabilizes p53 and induces cell cycle arrest and apoptosis in gastric cancer.
Zhang Y; Shi Y; Li X; Du W; Luo G; Gou Y; Wang X; Guo X; Liu J; Ding J; Wu K; Fan D
J Gene Med; 2010 Feb; 12(2):147-56. PubMed ID: 20020415
[TBL] [Abstract][Full Text] [Related]
32. Toxicology profiles of a novel p53-armed replication-competent oncolytic adenovirus in rodents, felids, and nonhuman primates.
Su C; Cao H; Tan S; Huang Y; Jia X; Jiang L; Wang K; Chen Y; Long J; Liu X; Wu M; Wu X; Qian Q
Toxicol Sci; 2008 Nov; 106(1):242-50. PubMed ID: 18703561
[TBL] [Abstract][Full Text] [Related]
33. The high levels of p53 present in adenovirus early region 1-transformed human cells do not cause up-regulation of MDM2 expression.
Grand RJ; Lecane PS; Owen D; Grant ML; Roberts S; Levine AJ; Gallimore PH
Virology; 1995 Jul; 210(2):323-34. PubMed ID: 7618270
[TBL] [Abstract][Full Text] [Related]
34. Analyses of single-amino-acid substitution mutants of adenovirus type 5 E1B-55K protein.
Shen Y; Kitzes G; Nye JA; Fattaey A; Hermiston T
J Virol; 2001 May; 75(9):4297-307. PubMed ID: 11287579
[TBL] [Abstract][Full Text] [Related]
35. Genetically modified adenoviruses against gliomas: from bench to bedside.
Gomez-Manzano C; Yung WK; Alemany R; Fueyo J
Neurology; 2004 Aug; 63(3):418-26. PubMed ID: 15304571
[TBL] [Abstract][Full Text] [Related]
36. Control of p53 expression by adenovirus 12 early region 1A and early region 1B 54K proteins.
Grand RJ; Owen D; Rookes SM; Gallimore PH
Virology; 1996 Apr; 218(1):23-34. PubMed ID: 8615026
[TBL] [Abstract][Full Text] [Related]
37. Advances in adenovirus-mediated p53 cancer gene therapy.
Tazawa H; Kagawa S; Fujiwara T
Expert Opin Biol Ther; 2013 Nov; 13(11):1569-83. PubMed ID: 24107178
[TBL] [Abstract][Full Text] [Related]
38. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
[TBL] [Abstract][Full Text] [Related]
39. The adenovirus E4orf6 protein contributes to malignant transformation by antagonizing E1A-induced accumulation of the tumor suppressor protein p53.
Nevels M; Spruss T; Wolf H; Dobner T
Oncogene; 1999 Jan; 18(1):9-17. PubMed ID: 9926915
[TBL] [Abstract][Full Text] [Related]
40. Development of novel E1-complementary cells for adenoviral production free of replication-competent adenovirus.
Farson D; Tao L; Ko D; Li Q; Brignetti D; Segawa K; Mittelstaedt D; Harding T; Yu DC; Li Y
Mol Ther; 2006 Aug; 14(2):305-11. PubMed ID: 16697707
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
